Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis

Barbara Cannella, Stefanie Gaupp, Ronald Tilton, Cedric S. Raine

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The integrin VLA-4 has been shown to play a key role in the entry of antigen-specific T cells into the CNS during autoimmune demyelination. Treatment of animals with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, with antibodies to VLA-4 is known to suppress acute disease. In the present study, a synthetic antagonist of VLA-4 (TBC 3486) was injected subcutaneously into mice adoptively sensitized for chronic relapsing EAE. TBC 3486 was administered daily for 14 days at early (before acute signs) and late time points (during chronic disease). Early treatment led to marked delay in disease onset and reduction in clinical severity and demyelination. After termination of treatment, clinical severity remained lower than in controls for more than 1 week. TBC 3486-treated animals showing no clinical signs (at the height of disease in controls) displayed moderate levels of inflammation but little damage to myelin. Late administration of TBC 3486 to animals with chronic EAE had no effect clinically. Immunocytochemistry and Western blotting of CNS tissue from acutely treated animals supported a moderate shift toward a Th2-type cytokine profile after treatment. Thus, TBC 3486 effectively delayed and reduced the acute (but not chronic) phase of EAE, and this amelioration correlated with changes in the inflammatory molecule profile.

Original languageEnglish (US)
Pages (from-to)407-416
Number of pages10
JournalJournal of Neuroscience Research
Volume71
Issue number3
DOIs
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Integrin alpha4beta1
Autoimmune Experimental Encephalomyelitis
Demyelinating Diseases
Acute Disease
Therapeutics
Myelin Sheath
Integrins
Multiple Sclerosis
Chronic Disease
Western Blotting
Immunohistochemistry
3-(1,3-benzodioxol-5-yl)-3-((((-1-((bis(2-thienylmethyl)amino)carbonyl)pentyl)amino)carbonyl)amino)propanoic acid
Cytokines
Inflammation
T-Lymphocytes
Antigens
Antibodies

Keywords

  • Adhesion molecules
  • CNS autoimmunity
  • Multiple sclerosis
  • Myelin

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis. / Cannella, Barbara; Gaupp, Stefanie; Tilton, Ronald; Raine, Cedric S.

In: Journal of Neuroscience Research, Vol. 71, No. 3, 01.02.2003, p. 407-416.

Research output: Contribution to journalArticle

Cannella, Barbara ; Gaupp, Stefanie ; Tilton, Ronald ; Raine, Cedric S. / Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis. In: Journal of Neuroscience Research. 2003 ; Vol. 71, No. 3. pp. 407-416.
@article{7e9935ce79d144e2a54ba7a29186ff1c,
title = "Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis",
abstract = "The integrin VLA-4 has been shown to play a key role in the entry of antigen-specific T cells into the CNS during autoimmune demyelination. Treatment of animals with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, with antibodies to VLA-4 is known to suppress acute disease. In the present study, a synthetic antagonist of VLA-4 (TBC 3486) was injected subcutaneously into mice adoptively sensitized for chronic relapsing EAE. TBC 3486 was administered daily for 14 days at early (before acute signs) and late time points (during chronic disease). Early treatment led to marked delay in disease onset and reduction in clinical severity and demyelination. After termination of treatment, clinical severity remained lower than in controls for more than 1 week. TBC 3486-treated animals showing no clinical signs (at the height of disease in controls) displayed moderate levels of inflammation but little damage to myelin. Late administration of TBC 3486 to animals with chronic EAE had no effect clinically. Immunocytochemistry and Western blotting of CNS tissue from acutely treated animals supported a moderate shift toward a Th2-type cytokine profile after treatment. Thus, TBC 3486 effectively delayed and reduced the acute (but not chronic) phase of EAE, and this amelioration correlated with changes in the inflammatory molecule profile.",
keywords = "Adhesion molecules, CNS autoimmunity, Multiple sclerosis, Myelin",
author = "Barbara Cannella and Stefanie Gaupp and Ronald Tilton and Raine, {Cedric S.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1002/jnr.10487",
language = "English (US)",
volume = "71",
pages = "407--416",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis

AU - Cannella, Barbara

AU - Gaupp, Stefanie

AU - Tilton, Ronald

AU - Raine, Cedric S.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - The integrin VLA-4 has been shown to play a key role in the entry of antigen-specific T cells into the CNS during autoimmune demyelination. Treatment of animals with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, with antibodies to VLA-4 is known to suppress acute disease. In the present study, a synthetic antagonist of VLA-4 (TBC 3486) was injected subcutaneously into mice adoptively sensitized for chronic relapsing EAE. TBC 3486 was administered daily for 14 days at early (before acute signs) and late time points (during chronic disease). Early treatment led to marked delay in disease onset and reduction in clinical severity and demyelination. After termination of treatment, clinical severity remained lower than in controls for more than 1 week. TBC 3486-treated animals showing no clinical signs (at the height of disease in controls) displayed moderate levels of inflammation but little damage to myelin. Late administration of TBC 3486 to animals with chronic EAE had no effect clinically. Immunocytochemistry and Western blotting of CNS tissue from acutely treated animals supported a moderate shift toward a Th2-type cytokine profile after treatment. Thus, TBC 3486 effectively delayed and reduced the acute (but not chronic) phase of EAE, and this amelioration correlated with changes in the inflammatory molecule profile.

AB - The integrin VLA-4 has been shown to play a key role in the entry of antigen-specific T cells into the CNS during autoimmune demyelination. Treatment of animals with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, with antibodies to VLA-4 is known to suppress acute disease. In the present study, a synthetic antagonist of VLA-4 (TBC 3486) was injected subcutaneously into mice adoptively sensitized for chronic relapsing EAE. TBC 3486 was administered daily for 14 days at early (before acute signs) and late time points (during chronic disease). Early treatment led to marked delay in disease onset and reduction in clinical severity and demyelination. After termination of treatment, clinical severity remained lower than in controls for more than 1 week. TBC 3486-treated animals showing no clinical signs (at the height of disease in controls) displayed moderate levels of inflammation but little damage to myelin. Late administration of TBC 3486 to animals with chronic EAE had no effect clinically. Immunocytochemistry and Western blotting of CNS tissue from acutely treated animals supported a moderate shift toward a Th2-type cytokine profile after treatment. Thus, TBC 3486 effectively delayed and reduced the acute (but not chronic) phase of EAE, and this amelioration correlated with changes in the inflammatory molecule profile.

KW - Adhesion molecules

KW - CNS autoimmunity

KW - Multiple sclerosis

KW - Myelin

UR - http://www.scopus.com/inward/record.url?scp=0037308359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037308359&partnerID=8YFLogxK

U2 - 10.1002/jnr.10487

DO - 10.1002/jnr.10487

M3 - Article

VL - 71

SP - 407

EP - 416

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 3

ER -